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Abstract
Background: Investigation of microRNAs (miRNAs) in obesity, their genetic targets and influence by dietary modulators is of
great interest because it may potentially identify novel pathways involved in this complex metabolic disorder and influence
future therapeutic approaches. This study aimed to determine whether miRNAs expression may be influenced by
conjugated linoleic acid (CLA), currently used to induce fat loss.
Methodology/Principal Findings: We determined retroperitoneal adipose tissue (rWAT) expression of five miRNAs related
to adipocyte differentiation (miRNA-143) and lipid metabolism (miRNA-103 and -107) and altered in obesity (miRNA-221 and
-222), using the TaqManHMicroRNA Assay (Applied-Biosystems). In the first experiment, mice were fed with a standard fat
diet and orally treated with sunflower oil (control group) and 3 or 10 mg CLA/day for 37 days. In the second experiment,
mice were fed with a high fat diet for 65 days. For the first 30 days, mice received the same doses of CLA described above
and, from that time onwards, animals received a double dose. Results showed that expression of selected miRNAs was
modified in response to CLA treatment and metabolic status. Interestingly, a strong correlation was observed between miR-
103 and -107 expression, as well as miR-221 and -222 in both experiments. Moreover, changes in miRNAs expression
correlated with several adipocyte gene expressions: miR-103 and -107 correlated with genes involved in fatty acid
metabolism whereas miR-221 and miR-222 correlated with the expression of adipocytokines. Regarding the minor changes
observed in miR-143 expression, no differences in expression of adipogenic markers were observed.
Conclusions/Significance: Although elucidating the functional implications of miRNAs is beyond the scope of this study,
these findings provide the first evidence that miRNAs expression may be influenced by dietary manipulation, reflecting or
even contributing to the new metabolic state originated by CLA treatment.
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Introduction
In the last decade, a novel class of RNA regulatory genes known
as miRNAs has been found to introduce a new level of gene
regulation in eukaryotes [1]. miRNAs are transcribed as long
primary-miRNAs (pri-miRNA) that encode a single miRNA or a
cluster of miRNA species. Genomic mapping has revealed that
pri-miRNA species are encoded within noncoding genomic
sequences as well as in introns or, less frequently exons, of
protein-coding genes. The processing of pri-miRNAs is initiated in
the nucleus and is further continued in the cytoplasm giving rise to
a 19–22 bp long mature miRNA. The mature miRNA is then
incorporated into a protein complex, the RNA-induced silencing
complex, where the miRNA strand anneals to the 39 untranslated
regions of target mRNAs to promote mRNA degradation or
translational repression, but in some cases, increases its transla-
tional activity [2]. The versatility of miRNA-mediated gene
regulation is evidenced by the finding that individual miRNAs can
target hundreds of genes while individual mRNAs can be targeted
by multiple miRNAs, allowing for enormous complexity and
flexibility in their regulatory potential [3–6].
Many miRNAs are conserved across species and intervene in a
variety of physiological processes including growth, differentiation,
development and energy metabolism. The first evidence for
participation of miRNAs in lipid metabolism came from a study in
Drosophila melanogaster, in which miR-14 was identified as necessary
for normal fat metabolism [7]. In mammals, miRNAs have been
shown to modulate adipocyte differentiation [8–11], cholesterol
and lipid homeostasis in liver [12,13] as well as insulin secretion
and signalling [14,15]. Recent papers have observed an associa-
tion between the expression of specific miRNAs and obesity [16–
19] supporting the fact that miRNAs may play a role in the
pathological development of obesity and also leading to the
hypothesis that miRNAs may represent a new class of adipogenic
regulators with potential therapeutic interest against obesity.
However, no effects on the impact of supplementation with
nutrients that modulate body composition on the expression of
miRNAs have been described yet.
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e13005Among nutrients, CLA, which refers to a group of positional
and geometric isomers of linoleic acid, has been reported to reduce
fat deposition both in animals (reviewed in [20]) and, to a lesser
extent, in humans (reviewed in [21]), and in consequence, is used
as dietary supplement for weight loss.
We have recently shown that moderate doses of an equimolar
mix of the two main active isomers are associated to lower fat
accretion in mice both under standard-fat [22] and high-fat diet
[23] without inducing liver steatosis and keeping insulin sensitivity.
In a further step, the purpose of the present study was to assess
whether miRNAs could play a role in the novel steady state
induced by CLA. Consequently, expression levels of selected
miRNAs (miR-143, miR-103, miR-107, miR-221 and miR-222)
which seem to be related to adipose biology were studied in
adipose tissue of mice treated with CLA. We found that their
expression was modified in response to CLA treatment and
metabolic status, furthermore strong correlations were observed
between their expressions and/or with several adipocyte gene
expressions.
Results
Adipose tissue miRNAs expression
CLA was shown to modulate the expression of selected miRNA
in adipose tissue in a specific manner, reflecting the impact of the
type of diet, the metabolic status and the CLA dose (Figure 1). The
lowest dose of CLA did not cause any change in miR-143
expression, either in experiment 1 (Exp1) or experiment 2 (Exp2).
However, the highest doses of CLA produced a decrease in each
experimental design (by 20%) although only reached statistically
significance in Exp1, when comparing CLA treated groups
(P,0.05). No changes in miR-103 were observed by CLA
treatment in either of the experiments. In Exp1, miR-107 showed
a dose-dependent decrease in its expression, which attained
statistical significance at the highest dose (CLA2) with respect to
both CLA1 and control group (P,0.05). Interestingly, under high-
fat diet (Exp2) miR-107 showed a different expression pattern
depending on the dose. A 40% increase (P,0.05) with respect to
the control value was found with the lowest dose (CLA3 group) in
contrast with the 46% decrease (P,0.01) with respect to the
control group that was observed at the highest dose (CLA4). miR-
221 expression was not affected in Exp1 and only the highest dose
of CLA in Exp2 (CLA4) produced a significant increase of miR-
221 with respect to both CLA3 and control groups (P,0.01).
Concerning miR-222 expression, a tendency to increase expres-
sion with the dose was seen in Exp1, although only the 75%
increase produced in CLA2 group was statistically significant
compared to the control group (P,0.01). In Exp2, miR-222
expression increased with the highest dose (CLA4 group) but did
not reach statistical significance.
Relationship within miRNAs expression
We further tested the hypothesis that miRNAs are expressed in
a coordinated manner as a response to the remodelation of
adipose tissue by CLA treatment. Data concerning the correlations
within their expression levels confirmed that the expression of
miRNAs was tightly correlated, particularly under normal-fat
feeding (Exp1) (Table 1). In fact, expression of all miRNAs tested
was significant and highly correlated within themselves, except for
the case of miR-222 which was only correlated with miR-103 and
miR-221. This strong association was partially lost in Exp2, with
CLA treatment under high-fat feeding, in which the only
correlations maintained were between miR-103 and miR-143;
mir103 and miR-107; and miR-221 and miR-222 (Table 1).
Expression of adipogenic marker genes
Since CLA treatments seem to alter common adipocyte gene
expression, we used RT-PCR to analyze expression levels of some
adipogenic marker genes such as glucose transporter type 4
(Glut4), lipoprotein lipase (Lpl), peroxisome proliferator activator
receptor gamma 2 (PPARc2) and CCAAT/enhancer binding
protein alpha (C/EBPa). In Exp1 under a stardard-fat diet
(Table 2) no differences in Lpl or the transcription factor PPARc2
were observed by CLA treatment. Glut4 showed a statistically
significant increase with the lowest dose (CLA1) with respect to
both CLA2 and control group (P,0.01). C/EBPa slightly
decreased with the highest dose but only reached statistical
significance when comparing with the lowest dose (CLA1 group)
(P,0.01). CLA treatment did not produce changes in the
expression of these genes in Exp2 (Table 2).
Correlations between miRNAs and adipocyte gene
expression
We further analyzed the expression of more adipocyte related
genes with the aim to determine the potential relationship between
the expression of the selected miRNAs and the adipocyte
phenotype. In Exp1, miR-143 correlated positively with adipo-
nectin (r=0.357, P,0.05) and leptin expression (r=0.358,
P,0.05); miR-103 was correlated with two key markers of lipid
metabolism, fatty acid synthase (Fasn, r=0.378, P,0.05) and
muscle carnitine palmitoyltransferase 1b (Cpt1b, r=0.404,
P,0.05); miR-107 correlated with genes involved in fatty acid
oxidation such as uncoupling protein 2 (Ucp2, r=20.339,
P,0.05) and Cpt1b (r=0.467, P,0.01) as well as with C/EBPa
(r=0.370, P,0.05) (Table 3). miR-222 showed significant
correlations with an array of genes related to adipocyte
metabolism including Glut4 (r=20.400, P,0.05); genes related
to lypolisis such as hormone sensitive lipase (HSL, r=20.379,
P,0.05) and patatin-like phospolipase domain containing 2
(Pnpla2, r=20.346, P,0.05); lipogenesis such as PPARc2
(r=20.396, P,0.05), Fasn (r=20.416, P,0.05), stearoyl-Coen-
zyme A desaturase 1 (Scd1, r=20.392, P,0.05); fatty acid
oxidation such as Ucp2 (r=0.525, P,0.01); and adipocytokines:
adiponectin (r=20.385, P,0.05) and tumor necrosis factor alpha
(TNFa, r=0.644, P,0.01) (Table 3). miR-221 was also specifi-
cally correlated with the expression of TNFa (r=0.385, P,0.05)
(Table 3). In Exp2, miR-107 expression in adipocytes was
significantly correlated with the expression of Lpl (r=20.428,
P,0.05), PPARa (r=0.494, P,0.05) and TNFa (r=20.510,
P,0.05), additionally under high-fat feeding, the correlation found
by CLA under normal-fat feeding between miR-107 and Cpt1b
(r=0.466, P,0.05) remained significant (Table 4). The high
number of correlations with miR-222 was not found in Exp2.
Correlation found for miR-221 and TNFa in Exp1 was
maintained in Exp2 (r=0.434, P,0.05) and a significant negative
correlation between adiponectin and miR-221 (r=20.444,
P,0.05) was also identified (Table 4). Significant and non-
significant correlations of both experiments were showed in the
Table S1 (Exp1) and Table S2 (Exp2).
Discussion
We have previously reported that the use of moderate doses of
CLA reduces body fat accretion in mice maintained on different
dietary regimes (Exp1 and Exp2) [22,23]. In both experiments,
the rWAT was the most sensitive to the effects of CLA,
decreasing up to 67% under CLA treatment in comparison with
controls. Therefore, this adipose tissue was selected to assess
whether CLA treatment could produce any impact on miRNAs
Oral CLA Modulates MicroRNAs
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fat mass have been proposed such as increased energy
expenditure, regulation of genes encoding for enzymes involved
in lipid synthesis, promotion of adipocyte apoptosis or decreased
preadipocyte proliferation and differentiation (reviewed in
[20,24]). The complex response to CLA in adipose tissue is likely
to take place through a CLA-mediated modulation of major
metabolic regulators which are not totally known. In agreement
with this assumption, the present study has demonstrated that
changes in miRNA expression occur in adipose tissue after CLA
treatment, suggesting a novel level of regulation by which CLA
might exert its effects.
Figure 1. Relative expression of miRNAs of mice maintained on different dietary regimes and treated with CLA. After CLA treatment,
expression levels of miRNAs were measured by real-time PCR in rWAT of mice fed a standard-fat diet (A) or a high-fat diet (B). Data are means 6 SEM of
n=10–11 mice in Exp1 and n=6–8 mice in Exp2. Mean values with unlike letters are significantly different (P,0.05); one-factor ANOVA followed by LSD test.
doi:10.1371/journal.pone.0013005.g001
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the regulation of adipocyte differentiation and in consequence may
play a key role in the pathological development of obesity
[8,11,25]. As potential targets of the action of CLA, we focused the
study on five selected miRNAs (miR-143, miR-103, miR-107,
miR-221 and miR-222) which, to a certain extent, have been
shown to be involved in adipocyte differentiation and/or
associated with obesity.
MiR-143 was the first miRNA associated with regulation of
adipocyte differentiation. Its expression increases in differentiating
adipocytes, and antisense oligonucleotides against miR-143 inhibit
human cultured adipocyte differentiation and lead to a decrease in
triglyceride accumulation and the downregulation of PPARc2,
adipocyte fatty acid binding protein and Glut4 [8], although this
has not been found in 3T3-L1 cells [9]. Later on it was
demonstrated that in mesenteric fat, miR-143 expression is
upregulated in mice fed a high-fat diet and this was associated
with elevated body and mesenteric fat weight as well as with
markers of adipocyte differentiation [16]. Accordingly, a decrease
in expression of miR-143 by CLA would justify a lower adipogenic
capacity and, would therefore contribute to the decrease of fat
stores observed in adipose tissue with CLA treatment. However,
our data showed small changes, if any, in the expression levels of
miR-143. Only the highest CLA dose assayed in each experiment
caused a slight decrease in miR-143 expression, but not
significantly different from controls. In accordance, gene expres-
sion of adipogenic markers such as Glut4, Lpl, PPARc2 and C/
EBPa was not decreased by CLA treatment in either of the
experiments, suggesting that the body fat lowering effect of CLA
observed in our conditions was unlikely to be a consequence of a
reduction in the adipogenic capacity.
Another aspect of interest concerns miR-103 and miR-107
regulation by CLA. Some miRNAs originate from introns of known
genes; in this case, they can be co-transcribed with the ‘parent’
mRNAs or independently [26–29]. For instance, miR-107, miR-
103-1 and miR-103-2 reside in the sense orientation in intron 5 of
the three panthothenate kinase (PANK) gene family members,
PANK1, PANK3 and PANK2, respectively. A computational study
predicted that this family of miRNAs affects multiple target genes in
metabolic pathways in a manner that points to a coordinated
function with the PANK genes, which are central players in
regulating intracellular Co-enzyme A [30–32]. This has been
further supported by experimental data showing that induction of
miR-103 and -107 during in vitro adipogenesis is accompanied by
induction of the respective PANK gene expression [11]. We found
high and significant correlations between the expression of miR-103
and -107 in both experimental settings suggesting coordinated
expression of both miRNAs. Interestingly, in Exp1, miR-107 was
Table 1. Correlations within miRNAs expression in mice treated with CLA under standard diet or a high-fat diet.
Exp1 (standard-fat diet) Exp2 (high-fat diet)
miR-143 miR-103 miR-107 miR-221 miR-222 miR-143 miR-103 miR-107 miR-221 miR-222
miR-143 0.677** 0.915** 0.622** 0.249 0.754** 0.418 -0.033 0.123
miR-103 0.696** 0.654** 0.393* 0.563** 0.183 0.312
miR-107 0.589** 0.197 -0.269 0.011
miR-221 0.787** 0.831**
The comparison between miRNAs expression levels in rWAT was done by the Pearson Chi-square test.
Statistical significance (2-tailed)
*P,0.05,
**P,0.01.
doi:10.1371/journal.pone.0013005.t001
Table 2. Adipogenic gene expression of mice treated with
CLA under standard diet or a high-fat diet.
Exp1 (standard-fat diet) Exp2 (high-fat diet)
Control CLA1 CLA2 Control CLA3 CLA4
Glut4 10065
a 12967
b 84610
a 100612 117610 112610
Lpl 10069 10565 10269 100659 0 66 10069
C/EBPa 10066
ab 11169
a 8166
b 10068 120611 10069
PPARc2 10067 107668 7 68 100669 6 658 5 68
The expression levels of adipocyte differentiation markers (Glut4, Lpl, C/EBPa,
and PPARc2) were analyzed by RT-PCR.
Data are means 6 SEM of 8–12 mice in Exp1 and of 7 mice in Exp2. Means in a
row without a common letter differ, P,0.05; one-factor ANOVA followed by
LSD test.
doi:10.1371/journal.pone.0013005.t002
Table 3. Significant correlations between adipocyte genes
expression and miRNAs in mice fed with a standard-fat diet
and treated with CLA.
Experiment 1 (standard-fat diet)
miR-143 miR-103 miR-107 miR-221 miR-222
Glut4 20.400*
C/EBPa 0.370*
PPARc2 20.396*
Fasn 0.378* 20.416*
Scd1 20.392*
Pnpla2 20.346*
HSL 20.379*
Cpt1b 0.404* 0.467**
Ucp2 20.339* 0.525**
Adiponectin 0.357* 20.385*
Leptin 0.358*
TNFa 0.385* 0.644**
The comparison between miRNAs and adipocyte gene expression in rWAT was
done by the Pearson Chi-square test. Statistical significance (2-tailed)
*P,0.05,
**P,0.01.
doi:10.1371/journal.pone.0013005.t003
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was correlated with the expression of two limiting enzymes in fatty
acid metabolism, such as Fasn and Cpt1b, suggesting that CLA
intake might contribute, to some extent, to modulate the role of
these two miRNAs in channeling Acil-CoA derivatives to
lipogenesis and/or to oxidation. However, in Exp2 this situation
wasdifferent. Although expression levels ofmiR-103 didnot change
by CLA treatment, the associations of its expression with phenotype
markers of adipocytes were not found. Concerning expression of
miR-107, CLA altered the profile of its expression in both
experiments and this resulted in novel associations with adipocyte
gene expression, only the association with Cpt1b was sustained in
both experimental designs. The above data point out that the
potentialrole ofmodulationofmiRNAsin vivo ismore complex than
in vitro assays and, in addition, is affected by a number of external
factors such as obesity, dietary treatment, metabolic status, etc.
Additionally, a recent report described an inverse relation of
several miRNAs expression during adipogenesis and obesity. A set
of miRNAs (including miR-103, miR-107 and miR-143) are
induced during adipogenesis, which may play a role in accelerating
fat cell development, and then be downregulated in the obese state
[11]. Conversely, another set of miRNAs follows the opposite
response pattern, for example miR-222 and miR-221, which are
decreased during adipogenesis but upregulated in obese adipocytes
[11]. Inagreement with this pattern, wefounda high and significant
correlation between the expressions of these two miRNAs in both
experiments, but contrary to the above, the miRNAs did not follow
a parallel regulation of their expression under CLA treatment.
Although little is known about the adipocyte biology of both
miRNAs, treatment of differentiated 3T3-L1 adipocytes for 24 h
with TNFa has been shown to induce expression of both miRNAs,
which has been associated with the role of TNFa, as a major
macrophage-produced cytokine involved in chronic inflammation
[11], being largely responsible for inducing insulin resistance in
obese adipose tissue [33]. Our data point out that CLA was able to
counteract the joint expression profile of these two miRNAs
observed in the obese state, where both miRNAs increase
simultaneously [11] and this is therefore associated with adipocyte
dysfunction and insulin resistance [11], which was not observed in
our study using moderate doses of CLA [22,23]. In fact, one of the
phenotypic characteristics of the treatment with CLA in the
present study concerns the maintenance of glucose-insulin
homeostasis, which is unaltered in Exp1 [22] and, despite
moderate hyperglucemia and hyperinsulinemia in Exp2, insulin
sensitivity, assayed by the revised quantitative insulin sensitivity
check index is preserved in this experimental setting [23].
A schematic representation of the correlations found (Figure 2),
helps to show the interrelationships which take place in adipose
tissue between the expression of microRNAs and mRNAs under
CLA treatment. Interestingly, the main outcome is that the five
miRNAs constitute a highly correlated core of signals, particularly
under standard fat diet (Exp1). In addition, CLA treatment during
high fat feeding (Exp2) shows a dissociation between the pair of
miRNAs 221/222 and the others. Furthermore, the expression of
a number of markers of adipocyte function (including markers of
fatty acid synthesis and transport) correlates with the expression of
the miRNAs. All in all, the most relevant seems to be the role of
the adipokines adiponectin and TNFa, whose expression keeps the
correlation linked to the pair of miRNAs 221/222, irrespective of
the different set up between Exp1 and Exp2, therefore reflecting
the impact of CLA on adipose miRNAs.
In this context, we have previously found decreased production
of leptin (accompanying fat loss) which goes hand in hand with
decreased expression of adiponectin [22,23]. We have suggested
that the decrease in body fat accretion induced by CLA treatment
under these specific conditions, decreases leptin and goes hand in
hand with lower adiponectin levels, reaching a novel set point
between these two circulating adipocytokines, which is associated
with the maintenance of insulin sensitivity and a general trend of
decreased expression of inflammatory markers in adipose tissue
[22] such as monocyte chemotactic protein-1 (MCP1), interleukin-
6 (IL-6), inducible nitric oxide synthase (iNOS) and TNFa [22,23].
Although elucidating the functional implications of miRNAs is
beyond the scope of this study, our data show that specific
miRNAs are sensitive to dietary manipulation and reflect the
metabolic changes that take place under CLA treatment. These
results are the basis for novel ways in the field of research into
CLA. Research into miRNAs in obesity, their genetic targets and
influence by dietary modulators is of great interest because it may
potentially identify new pathways involved in this complex
metabolic disorder and influence future approaches to the
treatment of obesity [19,34]. However, further studies will be
needed to understand the role of miRNAs in CLA action and to
assess the potential of miRNA profiles to predict nutritional status
in which CLA might trigger beneficial effects.
Materials and Methods
Animals and diets
Male C57BL/6J mice from Charles River (Barcelona, Spain)
weighing 2060.2 g were housed in groups of four in plastic cages
and maintained on a 12-h light:dark cycle at 22uC. These mice
Table 4. Significant correlations between adipocyte genes expression and miRNAs in mice fed with a high-fat diet and treated
with CLA.
Experiment 2 (high-fat diet)
miR-143 miR-103 miR-107 miR-221 miR-222
Lpl 20.428*
PPARa 0.494*
Cpt1b 0.466*
Adiponectin 20.444*
TNFa 20.510* 0.434*
The comparison between miRNAs and adipocyte gene expression in rWAT was done by the Pearson Chi-square test. Statistical significance (2-tailed)
*P,0.05,
**P,0.01.
doi:10.1371/journal.pone.0013005.t004
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regimes. In Exp1 animals were fed ad libitum with a standard diet
(D12450B, Research Diets Inc, New Brunswick) which contains
10% calorie content as fat (25 g/100 g soybean oil and 20 g/
100 g lard), 70% calorie content as carbohydrate (315 g/100 g
corn starch, 35 g/100 g maltrodextrin 10, 350 g/100 g sucrose
and 50 g/100 g cellulose) and the remaining 20% as protein
(casein and L-cystine). In Exp2 animals were fed ad libitum with a
high fat diet (D12451, Research Diets Inc, New Brunswick) which
contains 45% calorie content as fat (25 g/100 g soybean oil and
177.5 g/100 g lard), 35% calorie content as carbohydrate (72.8 g/
100 g corn starch, 100 g/100 g maltrodextrin 10, 172.8 g/100 g
sucrose and 50 g/100 g cellulose)and the remaining 20% as
protein (casein and L-cystine). Food intake and body weight were
recorded every three days during the experiments. Fresh food was
provided to the mice biweekly.
All experimental procedures were performed according to both
national and institutional guidelines for animal care and use.
CLA Treatment
Mice from both experiments were orally treated with CLA. The
CLA used was Tonalin H TG 80 derived from safflower oil (kindly
provided by Cognis). Tonalin is composed of triglycerides
containing approximately 80% conjugated linoleic acids with a
50:50 ratio of the active CLA isomers cis-9, trans-11 and trans-10,
cis-12.
In Exp1, mice were randomly assigned to three experimental
groups (n=12 each group): sunflower oil (control), CLA1 or CLA2
group. Two different doses of CLA were assayed in this study:
CLA1 (0.15 g CLA/kg body weight) and CLA2 (0.50 g CLA/kg
body weight), taking as a reference the weight of the animals at the
beginning of the experiment. Therefore, animals received a daily
amount of Tonalin equivalent to 3 mg CLA/animal in CLA1
group and 10 mg/animal in CLA2 group for 37 days. Control
animals received an isocaloric dose of commercially available
sunflower olive oil.
In Exp2, mice were also assigned to three experimental oral
treatments (n=8 each group): sunflower oil (control), CLA3 or
CLA4 group for 65 days. For the first 30 days the same doses of
CLA used in Exp1 were assayed, then after 30 days of treatment
and until the end of the experiment, the dose of each group was
doubled. Therefore, animals received a daily amount of Tonalin
equivalent to 6 mg CLA/animal in CLA3 and 20 mg/animal in
CLA4 groups for the last 35 days of treatment. An adequate
amount of commercial sunflower oil was given to the animals to
achieve an isocaloric load between groups.
Sacrifice and tissue sampling
Mice from Exp1 were sacrificed under feeding conditions
whereas mice from Exp2 were fasted for 10 h before sacrifice.
Mice were anaesthetized by intraperitoneal injection of a mixture
of xilacine (10 mg/kg body weight) and ketamine (100 mg/kg
body weight). rWAT was rapidly removed, weighed, rinsed with
saline containing 0.1% diethyl pyrocarbonate (Sigma, Madrid,
Spain), frozen with nitrogen liquid, and stored at 270uC.
RNA extraction and gene expression analyses
Total RNA from rWAT was extracted using Tripure Reagent
(Roche Diagnostic Gmbh, Mannheim, Germany) according to the
manufacturer’s instructions. Isolated RNA was quantified using
Figure 2. Schematic representation of the correlations between the expression of adipose miRNAs and of key markers of adipocyte
metabolism. Correlations were found in mice fed a standard-fat diet (A) and a high-fat diet (B). Two levels of statistical significance have been
considered and the wider lines indicate the strongest correlation. The discontinuous line shows a non statistically significant correlation (p=0.418).
Positive correlations are listed in squared forms and the negative ones in round forms. The bold names indicate adipocyte markers that are correlated
with more than one miRNA.
doi:10.1371/journal.pone.0013005.g002
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confirmed by agarose gel electophoresis.
Gene expression was assessed by Real Time-PCR performed in
an Applied Biosystems StepOnePlus
TM Real-Time PCR System
(Applied Biosystems). For miRNAs measurements, RNA was first
reverse-transcribed and then amplified using the specific primers
and probes provided with the TaqManH MicroRNA Reverse
Transcription kit (Applied Biosystems). To determine the adipo-
cyte genes of interest, total RNA was reverse transcribed to cDNA
as previously described [22] and amplified with gene-specific
primers and Power SYBR Green PCR Master Mix (Applied
Biosystems). Primer sequences are listed in Table S3. Relative
quantification of a target gene was calculated based on efficiency
and the crossing point deviation of an unknown sample versus a
control, and expressed in comparison to a reference gene used to
normalize cDNA (U6 small nuclear RNA and 18S ribosomal
RNA for miRNAs and mRNAs target genes, respectively). Details
of the protocol are available in Text S1.
Statistical analysis
Data are presented as means 6 SEM. One-factor ANOVA was
used to determine the significance of the differences between
groups. If there was a significant difference, a Least Significant
Difference (LSD) test was used to determine the particular effect
that caused that difference. P,0.05 was statistically significant,
and different superscripts discriminate differences between groups.
Linear relationships between key variables were tested using
Pearson’s correlation coefficients. The analysis was performed
using the SPSS program for Windows version 16 (SPSS, Chicago,
IL, USA).
Supporting Information
Table S1 The comparison between miRNAs and adipocyte
gene expression in rWAT was done by the Pearson Chi-square
test. Statistical significance (2-tailed) P,0.05 (*), P,0.01 (**).
Found at: doi:10.1371/journal.pone.0013005.s001 (0.06 MB
DOC)
Table S2 The comparison between miRNAs and adipocyte
gene expression in rWAT was done by the Pearson Chi-square
test. Statistical significance (2-tailed) P,0.05 (*), P,0.01 (**).
Found at: doi:10.1371/journal.pone.0013005.s002 (0.06 MB
DOC)
Table S3 Target genes: C/EBPalpha, CCAAT/enhancer bind-
ing protein alpha; Cpt1b, muscle carnitine palmitoyltransferase
1b; Fasn, fatty acid synthase; Glut4, glucose transporter type 4;
HSL, hormone sensitive lipase; Lpl, lipoprotein lipase; Pnpla2,
patatin-like phospolipase domain containing 2; PPAR, peroxisome
proliferator activator receptor; Scd1, stearoyl-Coenzyme A
desaturase 1; Ucp, uncoupling protein. 18S was used for
normalization.
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